98%
921
2 minutes
20
Background: Multi-arterial coronary bypass grafting with the left internal mammary artery as a conduit has been shown to offer superior long-term survival compared to single-arterial coronary bypass grafting. Nevertheless, the selection of a secondary conduit between the right internal mammary artery and the radial artery remains controversial. Using a national cohort, we examined the relationships between the right internal mammary artery and the radial artery with acute clinical and financial outcomes.
Methods: Adults undergoing on-pump multivessel coronary bypass grafting with left internal mammary artery as the first arterial conduit were identified in the 2016 to 2020 Nationwide Readmissions Database. Patients receiving either the right internal mammary artery or the radial artery, but not both, were included in the analysis. Multivariable regression models were fitted to examine the association between the conduits and in-hospital mortality, as well as additional secondary outcomes.
Results: Of an estimated 49,798 patients undergoing multi-arterial coronary bypass grafting, 29,729 (59.7%) comprised the radial artery cohort. During the study period, the proportion of multi-arterial coronary bypass grafting utilizing the radial artery increased from 51.3% to 65.2% (nptrend <0.001). Following adjustment, the radial artery was associated with reduced odds of in-hospital mortality (adjusted odds ratio 0.44), prolonged mechanical ventilation (adjusted odds ratio 0.78), infectious complications (adjusted odds ratio 0.69), and 30-day nonelective readmission (adjusted odds ratio 0.77, all P < .05).
Conclusion: Despite no definite endorsement from surgical societies, the radial artery is increasingly utilized as a secondary conduit in multi-arterial coronary bypass grafting. Compared to the right internal mammary artery, the radial artery was associated with lower odds of in-hospital mortality, complications, and reduced healthcare expenditures. These results suggest that whenever feasible, the radial artery should be the favored conduit over the right internal mammary artery. Nevertheless, future studies examining long-term outcomes associated with these vessels remain necessary.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.surg.2024.04.011 | DOI Listing |
Cancer Treat Res Commun
August 2025
Faculty of Medicine, American University of Beirut, 1107 Beirut, Lebanon; Department of Surgery, Division of General Surgery, American University of Beirut, 1107 Beirut, Lebanon. Electronic address:
Background: Neoadjuvant chemotherapy (NACT) is used to reduce breast cancer size before surgery, allowing for breast conservation surgery (BCS) instead of mastectomy. However, concerns exist about higher positive margins and local recurrence rates.
Aims: This study compared the incidence of positive margins, local recurrence rates, and other oncologic outcomes of BCS performed either upfront or after NACT.
J Control Release
September 2025
Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, People's Republic of China. Electronic address:
Radiotherapy (RT) is a key component of comprehensive cancer treatment regimens; nevertheless, its concomitant immunosuppression may diminish therapeutic efficacy. In this study, we developed an injectable hydrogel system for the local delivery of PROteolysis TArgeting Chimeras (PROTACs), achieved by loading tumor cell membrane-fused liposome nanoparticles to enhance the anti-tumor effect. The system targeted Bromodomain-containing protein 4 (BRD4), and combined treatment with RT promoted DNA damage, reduced DNA repair and decreased tumor cell proliferation and survival.
View Article and Find Full Text PDFESMO Open
September 2025
Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium. Electronic address:
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), such as abemaciclib and ribociclib, have recently been incorporated as adjuvant strategy in combination with endocrine therapy (ET) for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer at higher risk of recurrence. However, despite a significant reduction in recurrence rates, a subset of patients still experiences distant metastatic spreading, with nearly 10% recurring during or shortly after adjuvant CDK4/6i completion, as observed in pivotal trials. To date, only one small retrospective study has described this emerging population while ongoing trials are not specifically addressing this scenario, leaving both the efficacy of postrelapse treatments and the biological background largely unknown.
View Article and Find Full Text PDFJ Gastroenterol
September 2025
Department of Gastroenterology, Kanagawa Cancer Center, 2-3-2, Nakao, Asahi-ku, Yokohama, 241-0815, Japan.
Background: Systemic chemotherapy with gemcitabine plus S-1 (GEM + S-1), GEM + CDDP plus S-1 (GEM + CDDP + S-1), or gemcitabine plus cisplatin (GEM + CDDP) is standard treatment for advanced biliary tract cancer (aBTC). We aimed to evaluate the efficacy and safety of combination chemotherapy in older patients with aBTC.
Methods: This multicenter prospective observational study (JON2104-B, UMIN000045156) included patients aged ≥ 70 years with aBTC.
Curr Probl Cardiol
September 2025
Internal Medicine Study Program, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA; Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA. Electronic address:
HER2-targeted therapies have dramatically improved outcomes for patients with HER2-positive breast cancer, but their potential for cardiotoxicity remains a critical clinical concern. Early trials reported high rates of cardiac dysfunction, particularly with concomitant anthracycline use, prompting the development of intensive cardiac monitoring strategies. However, emerging evidence suggests that most cardiotoxic events are asymptomatic, reversible, and rarely require permanent treatment discontinuation, particularly with newer agents such as antibody-drug conjugates.
View Article and Find Full Text PDF